主要研究方向重症复杂冠心病的介入治疗、心力衰竭的血流动力支持治疗、心脏介入设备技术的创新探索及心力衰竭的机制研究。

Interventional treatment of severe and complex coronary heart disease, hemodynamic support treatment of heart failure, innovative exploration of cardiac interventional equipment technology, and mechanism research of heart failure.

上海市医学会心血管病分会血脂与动脉粥样硬化学组委员

Member of the Lipid and Atherosclerosis Group, Cardiovascular Disease Branch of Shanghai Medical Association.

目前在研课题：

1.国家自然科学青年基因，DRG2调节DRP1泛素化修饰调控心肌线粒体重塑的功能与机制研究，82300431，2024.1-2026.12，30万，在研。

2.教育部高等公司科研发展中心，Lp-PLA2和sd LDL-C联合检测对冠心病/心肌梗死病情发展和预后风险评估价值研究，2023JQ025，2024.4-2025.5，10万，在研。

3.院内国家自然基金培育，DRG2调节DRP1泛素化修饰在心衰中的机制研究，04.03.21035，2022.9-2025.9，5万，在研。

4.东方医疗器械创新医工转化“破壳”计划，基于FBG传感的自动化做事血流动力学监控支持平台项目，2023.12-2024.12，5万，在研。

Current research projects:

1.National Natural Science Foundation for Young Scientists, Study on the function and mechanism of DRG2 regulating DRP1 ubiquitination modification in regulating myocardial mitochondrial remodeling, 82300431, from January 2024 to December 2026, 300,000 yuan, in progress.

2.Scientific Research and Development Center of Universities, Ministry of Education, Study on the value of combined detection of Lp-PLA2 and sd LDL-C in evaluating the disease progression and prognostic risk of coronary heart disease/myocardial infarction, 2023JQ025, from April 2024 to May 2025, 100,000 yuan, in progress.

3.In-hospital cultivation project for National Natural Science Foundation, Study on the mechanism of DRG2 regulating DRP1 ubiquitination modification in heart failure, 04.03.21035, from September 2022 to September 2025, 50,000 yuan, in progress.

4. "Breaking Shell" plan for medical-engineering transformation of medical device innovation in East China, Project of automated real-time hemodynamic monitoring and support platform based on FBG sensing, from December 2023 to December 2024, 50,000 yuan, in progress.

近五年发表的SCI文章：SCI articles published in recent five years:

1) Tang, Y., Feng, M., Su, Y., Ma, T., Zhang, H., Wu, H., Wang, X., Shi, S., Zhang, Y., Xu, Y., Hu, S., Wei, K., & Xu, D. (2023). Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy. Circulation, 147(22), 1684–1704.

2) Sun, Y., Ma, M., Cao, D., Zheng, A., Zhang, Y., Su, Y., Wang, J., Xu, Y., Zhou, M., Tang, Y., Liu, Y., Ma, T., Fan, A., Zhang, X., Zhu, Q., Qin, J., Mo, C., Xu, Y., Zhang, L., Xu, D.,Yue, R. (2023). Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP. Circulation research, 132(5), 586–600.

3) Ma, T., Huang, R., Xu, Y., Lv, Y., Liu, Y., Pan, X., Dong, J., Gao, D., Wang, Z., Zhang, F., Yan, C., Ong, S. B., Su, Y., & Xu, D. (2023). Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial. Journal of translational medicine, 21(1), 21.

4) Mohammed, A. Q., Abdu, F. A., Su, Y., Liu, L., Yin, G., Feng, Y., Zhang, W., Xu, Y., Xu, D., & Che, W. (2023). Prognostic Significance of Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. The Canadian journal of cardiology, 39(7), 971–980.

5) Wang Z, Pan X, Xu H, Wu Y, Jia X, Fang Y, Lu Y, Xu Y, Zhang J, Su Y. Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure. Front Cardiovasc Med. 2022 Feb 9;9:812654.

6) Su Y, Sun Y, Tang Y, Li H, Wang X, Pan X, Liu W, Zhang X, Zhang F, Xu Y, Yan C, Ong SB, Xu D. Circulating miR-19b-3p as a Novel Prognostic Biomarker for Acute Heart Failure. J Am Heart Assoc. 2021 Oct 19;10(20):e022304.

7) Ma M, Xu Y, Su Y, Ong SB, Hu X, Chai M, Zhao M, Li H, Fan X, Chen Y, Xu D, Xu X. Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2. Front Cardiovasc Med. 2021 Feb 23;8:628885. IF: 6.05

8) Su Y, Ma T, Wang Z, Dong B, Tai C, Wang H, Zhang F, Yan C, Chen W, Xu Y, Ye L, Tye GJ, Ong SB, Zhang J, Xu D. Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT-AHF trial. ESC Heart Fail. 2020 Sep 18;7(6):4465–71.

9) Wang W, Su Y, Wu C, Sun Y, Dai N, Chen W, Zhang J, Xu Y, Brindis RG, Xu D, Li J. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2020 Feb 3;20(1):53.

10) Zhu K, Ma T, Su Y, Pan X, Huang R, Zhang F, Yan C, Xu D. Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides. Front Cardiovasc Med. 2021 Jul 21;8:683418.